{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"resected stage II–IIIB non-small cell lung cancer","name":"ALCHEMIST Chemo-IO","nct_id":"NCT04267848","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alchemist-chemo-io-nct04267848. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONTINUANCE THERAPY: Patients then undergo observation.\n\nPatients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.\n\n(CLOSED AS OF UPDATE #7)","label":"Arm A (platinum doublet, observation)","type":"ACTIVE_COMPARATOR"},{"description":"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens\\* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.\n\nPatients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.","label":"Arm B (platinum doublet, sequential pembrolizumab)","type":"EXPERIMENTAL"},{"description":"INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens\\* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nCONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.\n\nPatients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo a MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.","label":"Arm C (platinum doublet, combination pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-01-31","type":"ESTIMATED"},"conditions":["Lung Non-Small Cell Carcinoma","Lung Non-Small Cell Squamous Carcinoma","Lung Non-Squamous Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8"],"enrollment":{"count":1210,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","JM8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Echocardiography Test","otherNames":["EC","Echocardiography"],"type":"PROCEDURE"},{"name":"Gemcitabine Hydrochloride","otherNames":["dFdCyd","Difluorodeoxycytidine Hydrochloride","Gemcitabine HCI","Gemzar","LY 188011","LY-188011","LY188011"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Observation Activity","otherNames":["Observation"],"type":"OTHER"},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["BCD-201","GME 751","GME751","Keytruda","Lambrolizumab","MK 3475","MK-3475","MK3475","Pembrolizumab Biosimilar BCD-201","Pembrolizumab Biosimilar GME751","Pembrolizumab Biosimilar QL2107","Pembrolizumab Biosimilar RPH-075","Pembrolizumab Biosimilar SB27","QL2107","RPH 075","RPH-075","RPH075","SB 27","SB-27","SB27","SCH 900475","SCH-900475","SCH900475"],"type":"BIOLOGICAL"},{"name":"Pemetrexed Disodium","otherNames":["Alimta","Almita","LY231514","N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt"],"type":"DRUG"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-11-04","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease free survival (DFS)","timeFrame":"From randomization to the first of either disease recurrence or death from any cause, assessed up to 5 years after accrual completion"}],"references":[{"citation":"Osarogiagbon RU, Cetnar JP, Aljumaily R. Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun;46(3):e518244. doi: 10.1200/EDBK-26-518244. Epub 2026 Jun 23.","pmid":"42335416","type":"DERIVED"},{"citation":"Frumm SM, Florez N, Lee JM, Rotow JK, Chaft JE. Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2026 Mar 24;24(4):e267005. doi: 10.6004/jnccn.2026.7005.","pmid":"41911908","type":"DERIVED"},{"citation":"Booth A, Hillman S, Laumann K, Zhao YQ, LeBlanc M, Chansky K, Giri S, Dill J, Johnson J, Kelley K, Martin L, Osarogiagbon RU, Morris MJ, Chiang AC, Kozono DE, Blanke CD, Galanis E, Gray JE, Stinchcombe TE, Aljumaily R, Morgensztern D, Mandrekar SJ. PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. J Thorac Oncol. 2026 Jul;21(7):103650. doi: 10.1016/j.jtho.2026.103650. Epub 2026 Feb 24.","pmid":"41747891","type":"DERIVED"},{"citation":"Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021 Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21.","pmid":"33878954","type":"DERIVED"}],"start_date":{"date":"2020-06-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","url":"https://clinicaltrials.gov/study/NCT04267848"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alchemist-chemo-io-nct04267848"}